Different types of tumor microvessels in stage I-IIIA squamous cell lung cancer and their clinical significance
Marina A Senchukova, Department of Oncology, Orenburg State Medical University, Orenburg 460000, Russia
Evgeniy A Kalinin, Department of Thoracic Surgery, Orenburg Regional Cancer Clinic, Orenburg 460021, Russia
Nadezhda N Volchenko, Department of Pathology, PA Hertzen Moscow Oncology Research Centre, Branch of National Medical Research Radiological Center, Moscow 125284, Russia
Author contributions: Senchukova MA designed and performed the research, and wrote the paper; Kalinin EA acquired and analyzed the data and contributed substantially to the conception and design of the study; Volchenko NN participated in the discussion of related data and revised and approved the final version; All the authors wrote and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Orenburg State Medical University (Russia, Orenburg), No. 281, dated 30 September 2021.
Informed consent statement: Patients were not required to give informed consent to the study because the study was retrospective and analyses were performed with anonymous clinical data obtained after each patient agreed to treatment via written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Data from patients included in the study in Statistica10 table or Excel table format can be provided upon request to the corresponding author at masenchukova@yandex.com.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Marina A Senchukova, MD, PhD, Professor, Department of Oncology, Orenburg State Medical University, Sovetskaya Street 6, Orenburg 460000, Russia. masenchukova@yandex.com
Received: December 27, 2023
Peer-review started: December 27, 2023
First decision: January 17, 2024
Revised: February 12, 2024
Accepted: March 28, 2024
Article in press: March 28, 2024
Published online: May 24, 2024
